Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: STARDUST trial
Jul 18, 2023•9 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. H. Tarik Kani talks to Dr. Axel Dignass (Germany) about his recent publication about the impact of Ustekinumab on health-related quality of life in moderate-to-severe Crohn’s disease which was an open-label, multicenter, randomized study evaluated the quality of life prospectively in Crohn’s patients who treated with Ustekinumab.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast